iPill Dispenser

iPill Dispenser
Greater Los Angeles Area
  • Overview
  • Team
  • Activities
Company description


The iPill Dispenser System is aiming to revolutionize the prescription drug dispensing market especially with an urgency to prevent the opioid crisis from worsening and affecting tomorrow’s patients.  Our proposal has won the FDA’s Innovation Challenge for the Opioid Use Disorder and was granted the “Breakthrough Medical Device” designation in 2019. The iPill System consists of a portable and tamper-resistant dispenser, a wearable respiratory sensor that communicate with the iPill app downloadable to patient’s phone that calls emergency services, provides personal authentication using biometric technology, cognitive behavior therapy module promoting emotional wellbeing, collects HIPAA-compliant blockchain data improving public health.



Awards and Mentions
  • 40083_5404
    The FDA designated the iPill dispenser a Breakthrough medical device to enhance the regulatory path to the market
  • 40083_5155
    From PharmaIntelligence. the iPill Dispenser was chosen as a finalist in the catagory of Best-Patient Focused Technical Development
  • 40083_5153
    The University of California Institute for Predictive Technology set out to find the best use of data to predict overdose. The iPill system collects data on cognitive behavior therapy, respiratory distress and 911 calls for entry into a blockchain tree to allow immediate access to data for entry into predictive analytics to manage population health.
  • 40083_5152
    The FDA set a challenge for companies to submit their products to address the opioid use disorder. Over 300 companies submitted entries and iPill Dispenser was the only medical device digital health product to be chosen
  • Business model

    Briefly discussed here.  A full business plan is available upon request.  The iPill won the 2018 Innovation Challenge for Opioid Use Disorder and our goal is to get an FDA mandate that all opioid require use of the iPill dispenser for dispensing.  The SUPPORT ACT of 2018 gives the FDA legislative ability to do so. The child resistant cap was developed in 1967 and the FDA mandate came in 1970.  Waiting for the mandate to be made, we will sell the value proposition to PBMs, insurers, and dentists  on the cost effectiveness of the iPill to increase profits and save lives.  We have premarketed the value proposition of a cost-effective solution to decrease the cost of member costs by preventing $12,000 ER visits, $28,000 hospital visits and $128,000 rehab stays.  They have all indicated that they would participate in pilot step studies once the IDE was filed.  Our study partners would be our first customers.  We have structured manufacturing with a strategic partner so we can produce enough supply to meet demand and we have structured supply chain to avoid the opioid quota limitations.

    Competitive advantage

    We won the 2018 Innovation Challenge for Opioid Use Disorder. Never has a dispenser won.  Our distinctive feature is as an integrated product.  We have a sensor for respiration that call 911 if respiratory distress is detected.  We have a cognitive behavioral therapy module that uses AI to group the most successful non-opioid interventions to distract opioid use, and we collect all the data in a blockchain tree to enter into predictive analytics for real-time population health management. We are a de novo 510K Class II which means we will be the predicate for competitors to follow. Our patented integrated product, being 1st to market and 1st in class will be able to apply for the Hatch-Waxman Act to give us 3 years of market exclusivity.